Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | P2RY12 | Q9H244 | 12/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881495 | 0.88 | P2RY12 (0.49) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL21574257 | 0.88 | HDAC6 (0.53) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL18294913 | 0.83 | P2RY12 (0.49) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL18294912 | 0.83 | HDAC6 (0.55) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL16624609 | 0.83 | HDAC6 (0.57) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL18311318 | 0.82 | P2RY12 (0.42) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL18294908 | 0.80 | HDAC6 (0.50) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL19505428 | 0.80 | HDAC6 (0.60) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL18542037 | 0.75 | TDP1 (0.57) | HDAC6HDAC3HDAC1HDAC7HDAC2 | |
| SCHEMBL23289011 | 0.75 | HDAC6 (0.78) | HDAC6HDAC3HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-3468559-B1 | METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HDAC INHIBITORS WITH BET INHIBITORS | DANA FARBER CANCER INST INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11813261-B2 | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813261-B2 | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230190744-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230190744-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11666569-B2 | Treatment of polycystic diseases with an HDAC6 inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) U.S. GOVERNMENT (US) | 2023-06-06 | — | — | US | disclosed |
| US-20150105383-A1 | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105358-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105358-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105384-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| WO-2015054175-A1 | COMBINATIONS OF HISTONE DEACTYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150105384-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105383-A1 | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| WO-2015054355-A1 | HDAC INHIBITORS, ALONE OR IN COMBINATION WITH PI3K INHIBITORS, FOR TREATING NON-HODGKIN'S LYMPHOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099744-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099744-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | HDAC5, HDAC6, HDAC9 | HDAC6 2/4885HDAC3 8/4885HDAC1 7/4885 |
| US-11813261-B2 | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia | BTK, HDAC2, HDAC4 | HDAC6 8/4885HDAC3 11/4885HDAC1 6/4885 |
| US-20230190744-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF | HDAC1, HDAC3, HDAC8 | HDAC6 11/4885HDAC3 2/4885HDAC1 1/4885 |
| US-20150105384-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | HDAC6 4/4885HDAC3 11/4885HDAC1 1/4885 |
| US-20150105383-A1 | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma | HDAC5, HDAC9, HDAC4 | HDAC6 10/4885HDAC3 8/4885HDAC1 5/4885 |
| US-20150099744-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS | HDAC6, HDAC2, HDAC5 | HDAC6 1/4885HDAC3 7/4885HDAC1 6/4885 |
| US-11666569-B2 | Treatment of polycystic diseases with an HDAC6 inhibitor | HDAC6, PKD1, PKD2 | HDAC6 1/4885HDAC3 17/4885HDAC1 4/4885 |
| US-20150105358-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | HDAC5, HDAC4, HDAC2 | HDAC6 10/4885HDAC3 6/4885HDAC1 5/4885 |
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | HDAC1, HDAC3, HDAC8 | HDAC6 4/4885HDAC3 2/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.